The use for sucralfate in peptic ulcer disease has diminished recently, but it is still the preferred agent for stress ulcer prevention.Sucralfate has also been used for the following conditions:

Active duodenal ulcer not related to NSAID use
Maintenance therapy for resolved duodenal ulcers
Gastric ulcer not related to NSAID use and gastritis due to GERD—Triple combination therapy with lansoprazole + cisapride +  sucralfate can significantly improve symptoms and quality of life and was more cost-effective than ranitidine combination group. Aphthous ulcer and stomatitis due to radiation or chemotherapy—The 2013 guidelines of the International Society of Oral Oncology does not recommended sucralfate for the prevention of oral mucositis in head and neck cancer patients receiving radiotherapy or chemoradiation due to a lack of efficacy found in a randomized controlled trial. Gastro-esophageal reflux disease during pregnancy—First-line drug therapy combined with lifestyle and diet modification. Stress ulcer prophylaxis—The use of sucralfate rather than H2 antagonists for stress ulcer prophylaxis, and measures to prevent aspiration, such as continuous subglottic suctioning, have been shown to reduce the risk of ventilator-associated pneumonia (VAP). Sucralfate is less effective for prophylaxis against gastrointestinal bleeding than either a PPI or H2-blocker. For that reason, it is not commonly used for stress ulcer prophylaxis.
Management
If the patient has a known allergen or trigger for the eosinophilic bronchitis, the recommended treatment is to avoid the triggers. If the cause of the eosinophilic bronchitis is unknown, the first line treatment is inhaled corticosteroids. Patients respond well to inhaled corticosteroids and their eosinophil counts in their sputum usually decrease after treatment.There has not been a study to determine the ideal dosage of inhaled corticosteroids for patients with eosinophilic bronchitis, and there is no consensus on whether the treatment should be discontinued once the patients symptoms resolve or to continue long-term. The use of oral corticosteroids for eosinophilic bronchitis is rare, but it may be considered when inhaled corticosteroids are ineffective in managing the symptoms. Epidemiology
Approximately 10–30% of people who present with a chronic cough are suspected to be symptomatic due to eosinophilic bronchitis. == References ==